Today's Technical View: Dynavax Technologies, Avanir Pharma, Warner Chilcott, and Actavis Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, July 23, 2013 LONDON, July 23, 2013 /PRNewswire/ -- On Monday, July 22, 2013, shares in drug companies ended mostly higher, tracking gains in the broader market which posted small gains. The major movers in the industry included Dynavax Technologies Corporation (NASDAQ: DVAX), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), Warner Chilcott Plc (NASDAQ: WCRX), and Actavis Inc. (NYSE: ACT). All these companies are tracked by AAAResearchReports.com. Free in-depth technical analysis on DVAX, AVNR, WCRX, and ACT are currently available upon sign up at: http://www.aaaresearchreports.com/register/ Shares in Dynavax Technologies Corporation ended slightly higher on Monday, tracking gains in the broader market. The company's shares fluctuated between $1.23 and $1.27 before finishing the day 0.40% higher at $1.25. A total of 939,212 shares were traded which is below the daily average volume of 5.09 million. The company's shares have gained 0.40% in the last three trading sessions as compared to a gain of 0.87% in the S&P 500. Sign up for free technical analysis on DVAX at: http://www.AAAResearchReports.com/DVAX072313.pdf Avanir Pharmaceuticals Inc.'s stock rose sharply on Monday, extending their gains from previous trading sessions. The company's shares hit a 52-week high of $5.05 before closing the day 3.33% higher at $4.97. A total of 3.80 million shares were traded which is above the daily average volume of 2.43 million. The company's shares have gained 9.47% in the last three trading sessions and 15.18% in the last one month, thus outperforming the S&P 500. Download free report on AVNR by registering at: http://www.AAAResearchReports.com/AVNR072313.pdf Shares in Warner Chilcott Plc moved higher on Monday, extending their gains from previous trading sessions. The company's shares fluctuated between $19.77 and $20.35 before ending the session 2.06% higher at $20.28. A total of 3.85 million shares were traded which is above the daily average volume of 3.64 million. The company's shares have gained 4.75% in the last three trading sessions, hence outperforming the S&P 500. The free report on WCRX can be downloaded by signing up now at: http://www.AAAResearchReports.com/WCRX072313.pdf Actavis Inc.'s stock moved higher on Monday, closing at $127.93, up 2.00% from previous trading session. The company's shares fluctuated between $125.02 and $128.53. A total of 1.91 million shares were traded which is above the daily average volume of 1.13 million. The company's shares have gained 4.79% in the last three trading sessions and 30.74% in the last three months, therefore outperforming the S&P 500 during the respective periods. Moreover, the stock is currently trading near its 52-week high of $133.00. A free report on ACT can be accessed by registering at: http://www.AAAResearchReports.com/ACT072313.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE AAA Research Reports Contact: AAAresearchreports.com Phone #: + 1(646)396-9126
Today's Technical View: Dynavax Technologies, Avanir Pharma, Warner Chilcott, and Actavis
Press spacebar to pause and continue. Press esc to stop.